![Thomas Mehrling](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Thomas Mehrling
Chief Executive Officer at
HELIX BIOPHARMA CORP.
Net worth: 50 290 $ as of 31/07/2026
Profile
Thomas J.
Mehrling is the founder of Laevoroc Oncology AG, founded in 2019, where Dr. Mehrling holds the title of Chief Executive Officer.
Dr. Mehrling was the founder of Mundipharma EDO GmbH, founded in 2013, where Dr. Mehrling held the title of Chief Executive Officer.
Dr. Mehrling is also the founder of Laevoroc Immunology AG..
Dr. Mehrling is Chief Executive Officer at Release Therapeutics SA since 2024.
Dr. Mehrling is Chief Executive Officer at Helix BioPharma Corp.
starting in 2025.
Dr. Mehrling is Chairman & Chief Executive Officer at Laevoroc Chemotherapy AG.
Dr. Mehrling was Managing Director-European Oncology at Mundipharma International Ltd. from 2003 to 2013.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 21/05/2026 | 47,000 ( 0.06% ) | 50 290 $ | 31/07/2026 |
Thomas Mehrling active positions
| Companies | Position | Start |
|---|---|---|
| HELIX BIOPHARMA CORP. | Chief Executive Officer | 10/04/2025 |
Laevoroc Oncology AG
 Laevoroc Oncology AG BiotechnologyHealth Technology Develops and manufactures cancer immunotherapies | Chief Executive Officer | 01/02/2019 |
Release Therapeutics SA
 Release Therapeutics SA BiotechnologyHealth Technology Develops first cell microencapsulation technology to deliver therapeutic proteins beyond the human blood-brain barrier | Chief Executive Officer | 27/06/2024 |
Former positions of Thomas Mehrling
| Companies | Position | End |
|---|---|---|
Mundipharma EDO GmbH
 Mundipharma EDO GmbH Miscellaneous Commercial ServicesCommercial Services Engages in research and development of therapies for cancer | Chief Executive Officer | 01/07/2019 |
Mundipharma International Ltd.
 Mundipharma International Ltd. Pharmaceuticals: MajorHealth Technology Develops and produces pharmaceutical products | Corporate Officer/Principal | 01/01/2013 |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
23
1st degree connections
5
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
Helix BioPharma Corp.
 Helix BioPharma Corp. Pharmaceuticals: MajorHealth Technology Develops drugs for the prevention and treatment of cancer | Health Technology |
Mundipharma International Ltd.
Mundipharma International Ltd. Pharmaceuticals: MajorHealth Technology Develops and produces pharmaceutical products | Health Technology |
Release Therapeutics SA
Release Therapeutics SA BiotechnologyHealth Technology Develops first cell microencapsulation technology to deliver therapeutic proteins beyond the human blood-brain barrier | Health Technology |
Mundipharma EDO GmbH
Mundipharma EDO GmbH Miscellaneous Commercial ServicesCommercial Services Engages in research and development of therapies for cancer | Commercial Services |
Laevoroc Oncology AG
Laevoroc Oncology AG BiotechnologyHealth Technology Develops and manufactures cancer immunotherapies | Health Technology |
- Stock Market
- Insiders
- Thomas Mehrling
